Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oculogenex Inc. is currently handling 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to the distinct examiner, ARON, KIMBERLY A, within a distinct art unit. ARON, KIMBERLY A is the busiest examiner with 1 pending office action, representing the company's total active workload.
This focus means that the outcome of the current prosecution depends on the interpretation of an individual within a specific technical department. For a practitioner, this environment suggests that building a consistent rapport with ARON, KIMBERLY A is a primary factor in navigating the USPTO. The absence of multiple distinct examiners or art units reduces the complexity of tracking various examiner preferences. Consequently, the company's immediate patent strategy is tied to the progress of this individual application. The concentrated nature of the portfolio allows for a streamlined approach to addressing any technical rejections within the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARON, KIMBERLY A | 1 | 54.7% | +34.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | ARON, KIMBERLY A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | ARON, KIMBERLY A | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18760919 | AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY | ARON, KIMBERLY A | 1633 | §102§112 | Non-Final OA | — | Pending | Jul 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOculogenex Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kimberly A Aron has the most, with 1 of Oculogenex Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
